136 related articles for article (PubMed ID: 19540329)
1. Characterization of the phospholipidogenic potential of 4(1H)-pyridone antimalarial derivatives.
Almela MJ; Torres PA; Lozano S; Herreros E
Toxicol In Vitro; 2009 Dec; 23(8):1528-34. PubMed ID: 19540329
[TBL] [Abstract][Full Text] [Related]
2. Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats.
Miyamoto S; Matsumoto A; Mori I; Horinouchi A
Toxicol Mech Methods; 2009 Oct; 19(8):477-85. PubMed ID: 19793005
[TBL] [Abstract][Full Text] [Related]
3. Validation of an in vitro screen for phospholipidosis using a high-content biology platform.
Morelli JK; Buehrle M; Pognan F; Barone LR; Fieles W; Ciaccio PJ
Cell Biol Toxicol; 2006 Jan; 22(1):15-27. PubMed ID: 16463016
[TBL] [Abstract][Full Text] [Related]
4. Phospholipidosis assay in HepG2 cells and rat or rhesus hepatocytes using phospholipid probe NBD-PE.
Bhandari N; Figueroa DJ; Lawrence JW; Gerhold DL
Assay Drug Dev Technol; 2008 Jun; 6(3):407-19. PubMed ID: 18537465
[TBL] [Abstract][Full Text] [Related]
5. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies.
Nioi P; Perry BK; Wang EJ; Gu YZ; Snyder RD
Toxicol Sci; 2007 Sep; 99(1):162-73. PubMed ID: 17567588
[TBL] [Abstract][Full Text] [Related]
6. High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis.
van de Water FM; Havinga J; Ravesloot WT; Horbach GJ; Schoonen WG
Toxicol In Vitro; 2011 Dec; 25(8):1870-82. PubMed ID: 21651975
[TBL] [Abstract][Full Text] [Related]
7. Detection of metabolic activation leading to drug-induced phospholipidosis in rat hepatocyte spheroids.
Takagi M; Sanoh S; Santoh M; Ejiri Y; Kotake Y; Ohta S
J Toxicol Sci; 2016 Feb; 41(1):155-64. PubMed ID: 26763403
[TBL] [Abstract][Full Text] [Related]
8. From the Cover: Potentiation of Drug-Induced Phospholipidosis In Vitro through PEGlyated Graphene Oxide as the Nanocarrier.
Yang L; Zhong X; Li Q; Zhang X; Wang Y; Yang K; Zhang LW
Toxicol Sci; 2017 Mar; 156(1):39-53. PubMed ID: 28013220
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced phospholipidosis is caused by blockade of mannose 6-phosphate receptor-mediated targeting of lysosomal enzymes.
Ikeda K; Hirayama M; Hirota Y; Asa E; Seki J; Tanaka Y
Biochem Biophys Res Commun; 2008 Dec; 377(1):268-74. PubMed ID: 18840403
[TBL] [Abstract][Full Text] [Related]
10. Cell-based fluorescence assay for evaluation of new-drugs potential for phospholipidosis in an early stage of drug development.
Fujimura H; Dekura E; Kurabe M; Shimazu N; Koitabashi M; Toriumi W
Exp Toxicol Pathol; 2007 Aug; 58(6):375-82. PubMed ID: 17408938
[TBL] [Abstract][Full Text] [Related]
11. Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells.
Atienzar F; Gerets H; Dufrane S; Tilmant K; Cornet M; Dhalluin S; Ruty B; Rose G; Canning M
Toxicol Sci; 2007 Mar; 96(1):101-14. PubMed ID: 17175557
[TBL] [Abstract][Full Text] [Related]
12. Predicting in vivo phospholipidosis-inducing potential of drugs by a combined high content screening and in silico modelling approach.
Bauch C; Bevan S; Woodhouse H; Dilworth C; Walker P
Toxicol In Vitro; 2015 Apr; 29(3):621-30. PubMed ID: 25668432
[TBL] [Abstract][Full Text] [Related]
13. Exploration of 4(1H)-pyridones as a novel family of potent antimalarial inhibitors of the plasmodial cytochrome bc1.
Bueno JM; Herreros E; Angulo-Barturen I; Ferrer S; Fiandor JM; Gamo FJ; Gargallo-Viola D; Derimanov G
Future Med Chem; 2012 Dec; 4(18):2311-23. PubMed ID: 23234553
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials.
Yeates CL; Batchelor JF; Capon EC; Cheesman NJ; Fry M; Hudson AT; Pudney M; Trimming H; Woolven J; Bueno JM; Chicharro J; Fernández E; Fiandor JM; Gargallo-Viola D; Gómez de las Heras F; Herreros E; León ML
J Med Chem; 2008 May; 51(9):2845-52. PubMed ID: 18396855
[TBL] [Abstract][Full Text] [Related]
15. Evaluation and validation of multiple cell lines and primary mouse macrophages to predict phospholipidosis potential.
LeCureux L; Cheng CS; Herbst J; Reilly TP; Lehman-McKeeman L; Otieno M
Toxicol In Vitro; 2011 Dec; 25(8):1934-43. PubMed ID: 21767630
[TBL] [Abstract][Full Text] [Related]
16. Comparison of a genomic and a multiplex cell imaging approach for the detection of phospholipidosis.
Tilmant K; Gerets HH; Dhalluin S; Hanon E; Depelchin O; Cossu-Leguille C; Vasseur P; Atienzar FA
Toxicol In Vitro; 2011 Oct; 25(7):1414-24. PubMed ID: 21515356
[TBL] [Abstract][Full Text] [Related]
17. Adaptation of an in vitro phospholipidosis assay to an automated image analysis system.
Schurdak ME; Vernetti LA; Abel SJ; Thiffault C
Toxicol Mech Methods; 2007; 17(2):77-86. PubMed ID: 20020975
[TBL] [Abstract][Full Text] [Related]
18. A 96-well flow cytometric screening assay for detecting in vitro phospholipidosis-induction in the drug discovery phase.
Natalie M; Margino S; Erik H; Annelieke P; Geert V; Philippe V
Toxicol In Vitro; 2009 Mar; 23(2):217-26. PubMed ID: 19101623
[TBL] [Abstract][Full Text] [Related]
19. Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds.
Hanumegowda UM; Wenke G; Regueiro-Ren A; Yordanova R; Corradi JP; Adams SP
Chem Res Toxicol; 2010 Apr; 23(4):749-55. PubMed ID: 20356072
[TBL] [Abstract][Full Text] [Related]
20. Screening for the drug-phospholipid interaction: correlation to phospholipidosis.
Alakoskela JM; Vitovic P; Kinnunen PK
ChemMedChem; 2009 Aug; 4(8):1224-51. PubMed ID: 19551800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
